Reckitt stock fell about 5% in early trading on Wednesday after the consumer goods group said first-quarter core like-for-like net revenue rose only 1.3%.
The figure was well below the 2.9% analysts had expected, and warned that first-half adjusted operating margin would be roughly 200 basis points lower than a year earlier.
The update pointed to a familiar problem for the Dettol and Lysol maker: pricing is still doing some of the work, but volumes are not yet strong enough to reassure investors.
Europe is still doing the heavy lifting
The clearest weakness was in Europe, where Reckitt said revenue fell 4.2% in the quarter, with volumes down 4.5% and price/mix up just 0.3%.
The company blamed lower cold and flu incidence, softer category growth and a more promotional trading environment.
Reckitt said the regional pattern was broadly unchanged from the fourth quarter of 2025, which suggests the problem is not a one-off stumble but a more persistent demand issue.
That matters because Europe remains a large part of the group’s core business.
In the quarter, the region generated £873 million of net revenue, and the slide in seasonal OTC was enough to offset progress in premiumisation lines such as Finish Ultimate Plus.
Reckitt said those premium formats are helping mix, but the category backdrop is still too soft to deliver stronger top-line growth.
Pricing held up, but demand did not
The quarter also showed the tension at the heart of Reckitt’s current turnaround: pricing is still positive, but not enough to mask weak unit growth.
For Core Reckitt, price/mix added 2.3% in the quarter, while volume fell 1.0%.
Excluding seasonal OTC, core growth improved to 3.1%, which is better evidence that the non-seasonal portfolio is holding up more solidly than the winter-sensitive pharmacy products.
That split is important as emerging markets grew 7.6%, helped by double-digit growth in China and India, but even that was below expectations.
North America also softened, with core revenue down 0.9%, although volumes there rose 1.5% as non-seasonal brands performed well.
Why investors are still cautious
The stock reaction suggests the market is looking past the quarter’s surface resilience.
Reckitt said its full-year core like-for-like revenue guidance remains 4% to 5%, and management expects a sequential improvement as the cold and flu season resets.
But the company also warned that H1 margin pressure will come from stranded costs, lower seasonal incidence and higher commodity prices.
High oil and freight costs linked to the Middle East conflict are also expected to add to the squeeze.
That is why the market is treating this as more than a weather story.
Seasonal weakness can explain part of the miss, but not the broader pattern of subdued volume growth in developed markets and a less-than-expected showing from emerging markets.
The post Reckitt stock dips on Q1 miss: what’s really ailing the health giant? appeared first on Invezz
